Evidence map›Paper›PMID 42185645›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Immune Checkpoint Blockade Enhances the Abscopal Effect of [

Zhaoting Cheng, Huimin Zhou, Luoxia Liu, Ziqiang Wang, Shuang Song, Bo Yu, Jun Zhao, Xiaohua Zhu

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhaoting ChengDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease; National Center for Major Public Health Events, 1095 Jiefang Ave, Wuhan, Hubei, 430030, China.
Huimin ZhouDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease; National Center for Major Public Health Events, 1095 Jiefang Ave, Wuhan, Hubei, 430030, China.
Luoxia LiuDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease; National Center for Major Public Health Events, 1095 Jiefang Ave, Wuhan, Hubei, 430030, China.
Ziqiang WangDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease; National Center for Major Public Health Events, 1095 Jiefang Ave, Wuhan, Hubei, 430030, China.
Shuang SongDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease; National Center for Major Public Health Events, 1095 Jiefang Ave, Wuhan, Hubei, 430030, China.
Bo YuDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease; National Center for Major Public Health Events, 1095 Jiefang Ave, Wuhan, Hubei, 430030, China.
Jun ZhaoDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease; National Center for Major Public Health Events, 1095 Jiefang Ave, Wuhan, Hubei, 430030, China.
Xiaohua ZhuDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease; National Center for Major Public Health Events, 1095 Jiefang Ave, Wuhan, Hubei, 430030, China. evazhu@vip.sina.com.ORCID 0000-0003-0495-9510

Funding

National Natural Science Foundation of China 81901782National Natural Science Foundation of China 82272041, 82572277National Natural Science Foundation of China 82502403
6 · The paper itself

Abstract

purposeThe overexpression of somatostatin receptor (SSTR) in neuroendocrine neoplasms (NENs) provides a molecular basis for treatment with peptide receptor radionuclide therapy (PRRT). However, heterogeneous SSTR expression limits therapeutic efficacy. Immune checkpoint inhibitors (ICIs) enhance the abscopal effect of external radiotherapy. This study investigated whether combining PRRT using the SSTR antagonist [

methodsA bilateral SSTR2-heterogeneous murine melanoma model was established by contralateral implantation of B16F10-SSTR2 and B16F10-wildtype tumors. Mice received saline, PRRT, anti-PD-L1 mAb, or combination therapy. Tumor growth, survival, PET/CT imaging, histopathology, immune profiling (including PD-L1 expression, CD45

resultsPRRT monotherapy selectively inhibited SSTR2-positive tumors but showed minimal efficacy against SSTR2-negative tumors. Combination therapy significantly suppressed the growth of both tumors, prolonged survival, and reduced [

conclusionPRRT combined with PD-L1 blockade remodels the tumor immune microenvironment, elicits potent systemic antitumor immunity, and enhances the abscopal effect in SSTR2-heterogeneous tumors. This strategy may help address target-expression heterogeneity in radionuclide therapy.

Indexed as

Immune Checkpoint InhibitorsLutetiumMelanoma, ExperimentalOctreotideRadioisotopesReceptors, SomatostatinAnimalsB7-H1 AntigenFemaleMiceMice, Inbred C57BLOrganometallic CompoundsPositron Emission Tomography Computed TomographyB7-H1 AntigenImmune Checkpoint InhibitorsLutetiumLutetium-177OctreotideOrganometallic CompoundsRadioisotopesReceptors, SomatostatinAbscopal effectImmune checkpoint inhibitorPeptide receptor radionuclide therapySSTR antagonistSSTR heterogeneity

Identifiers

PMID42185645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.